

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 2666)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Genertec Universal Medical Group Company Limited (the “**Company**”) is pleased to announce that with effect from 25 July 2023, Ms. Wang Lin (“**Ms. Wang**”) is appointed as an executive Director.

Ms. Wang Lin (王琳女士), aged 48, has extensive experience in corporate governance. Ms. Wang served as a director and deputy general manager of General Technology Group Health and Elderly Care Sector Co., Ltd. (通用技術集團健康養老產業有限公司, “**GT-HECS**”), a subsidiary of China General Technology (Group) Holding Co., Ltd. (中國通用技術(集團)控股有限公司, “**GT-PRC**”) (the controlling shareholder of the Company) from August 2022 to July 2023, and served as the party secretary of GT-HECS from December 2022 to July 2023. From May 2019 to August 2022, she held several positions in a subsidiary of GT-PRC specialized in inspection, testing and certification, including the leader of the business group of inspection, testing and certification, the director and the general manager. From January 2020 to September 2021, she served as a director of China Automotive Engineering Research Institute Co., Ltd (中國汽車工程研究院股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 601965).

Ms. Wang obtained a bachelor’s degree (majored in organization work (機關工作專業)) in July 1999 from Xi’an Political College (西安政治學院), where she also received her master’s degree (majored in organization work (機關工作專業) and part-time) in February 2006. Ms. Wang was

qualified as a senior engineer (高級工程師) in December 2018 by the State Administration for Market Regulation of China (中華人民共和國國家市場監督管理總局).

Ms. Wang and the Company entered into a service contract on 25 July 2023, pursuant to which Ms. Wang was appointed as an executive Director with effect from 25 July 2023, and such appointment could be terminated by either Ms. Wang or the Company by giving not less than 90 days' notice in writing. Ms. Wang will hold office as an executive Director until completion of the next annual general meeting of the Company following her appointment and will then be eligible for re-election at that general meeting of the Company. Pursuant to the service contract, the remuneration of Ms. Wang as an executive Director will be considered by the remuneration committee of the Board and subsequently considered and approved by the Board.

As at the date of this announcement, except as disclosed above, Ms. Wang did not (i) have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) hold any other directorships in public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) hold other positions with the Company or its subsidiaries.

Save as disclosed above, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, there is no information in relation to the appointment of Ms. Wang that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

By order of the Board
**Genertec Universal Medical Group Company
Limited**
通用環球醫療集團有限公司
Peng Jiahong
Chairwoman of the Board

Beijing, PRC, 25 July 2023

As at the date of this announcement, the executive Directors are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive Directors are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-

executive Directors are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.